Symrise AG Stock Timeline

2021 Q1–Q2 (Apr 1, 2021)

Symrise completed its acquisition of Sensient's fragrance business unit for approximately €29.3 million. The deal included Sensient Fragrances S.A.U. and related assets. [1][2]

Market participants viewed this as targeted inorganic expansion in fragrance ingredients and naturals—a bolt-on that strengthened Symrise's fragrance and aroma-chemicals footprint while supporting the growth narrative without materially increasing capital intensity. Investors treated it as strategic consolidation within a fragmented supply base. [1][2]

The stock entered a moderate rally phase as the market digested the acquisition as accretive to fragrance segment growth.

2021 H2 (Aug 2021)

Symrise disclosed several smaller strategic stakes and disposals in 2021 reporting, including non-controlling interest transactions and pet-food market stake disclosures. [1]

The company reinforced its identity as acquisitive and active across segments—Fragrances, Nutrition, and Natural ingredients. Investors interpreted diversified M&A activity as evidence of disciplined portfolio building.

The stock consolidated with a positive bias following earlier gains.

2022 (full year) — broader macro headwinds (inflation, supply chain)

Symrise navigated high input cost inflation, logistics disruptions, and raw material pressure common to flavor and fragrance peers. The company focused on price and mix, along with cost pass-through strategies. [10]

Investor perception shifted from pure growth multiple to resilience and quality. Concerns emerged about margin pressure, yet recognition of pricing power and diversified end markets—food, fragrance, personal care—persisted. The growth story tempered to "resilient compounder" with near-term margin cyclicality. [10]

The stock moved through a volatile range as macro uncertainty weighed on sentiment.

2023 (calendar) — leadership change and strategic goal setting toward 2025

Jean-Yves Parisot emerged as new Group CEO, with his first AGM speech as CEO delivered in 2024. During this period, management reiterated medium-term targets of 5–7% CAGR and mid-20s EBITDA margin targets around 21% for 2025, while sharpening sustainability and net-zero focus. [13][4]

Investor perception evolved toward "structured transformation" under refreshed leadership. Focus shifted to execution of the ONE SYM transformation, margin expansion, and sustainability commitments. The stock was viewed as execution-dependent.

Breakout attempts interspersed with pullbacks characterized the technical picture as the market awaited clearer evidence of margin recovery.

2024 (FY reporting and transformation execution)

Symrise confirmed growth and profitability targets for 2025 and reported improved margin progression. Management emphasized the ONE SYM transformation, operational efficiency, and naturals strategy. [4][11]

Investor perception shifted more positively as evidence mounted for margin improvement and portfolio focus. The narrative moved from macro-vulnerable to improving compounder executing cost and transformation initiatives. Sustainability narrative bolstered premium positioning in naturals and fragrances. [4][11]

The stock rallied as confirmed guidance and margin trajectory reduced execution risk.

2025 (full year results disclosed early 2026 for FY 2025)

Symrise reported solid organic sales growth and strong profitability improvement for 2025. Adjusted EBITDA margin reached approximately 21.9% and adjusted EBITDA rose. Management recorded non-cash impairment charges related to Terpene and Swedencare businesses in Q4 2025 and completed portfolio updates including divestments of Terpene Ingredients and Aqua Feed. The ONE SYM program delivered cost savings and efficiency gains. [12][8]

The market treated 2025 as a proof point: improving margin profile, stronger cash flow (record business free cash flow margin), and active portfolio pruning signaled transition from cyclical recovery to durable margin expansion. Impairments were seen as one-off cleansing actions that clarified core strategy. Symrise's story consolidated into "quality growth with margin leverage." [12][15]

A significant rally occurred during 2025 as results beat and guidance reinforced confidence. Intermittent profit-taking followed impairments, though the stock established a higher base.

2026 H1 (through Aug 11, 2026)

Symrise reported solid H1 2026 performance with accelerating growth momentum in Q2 and announced a put option agreement to acquire Floral Concept, strengthening Premium Naturals in Pays de Grasse. The company continued active M&A and tuck-ins in naturals and fragrance. [6][7][9]

Investor perception as of mid-2026 positioned Symrise as a higher-quality, margin-improving specialty ingredients company continuing acquisitive expansion in premium naturals and fragrances. The market treated the company as an execution-oriented compounder with credible mid-term targets. Sentiment remained supportive, though valuation sensitivity to further M&A and organic acceleration persisted. [6][7]

The stock formed an uptrend with consolidation and new-range formation, currently trading at 91.68.